Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab

ConclusionsThis analysis has confirmed a prognostic effect of primary tumour location in patients withRAS wild-type metastatic colorectal cancer receiving first-line panitumumab plus FOLFIRI. Early tumour shrinkage was associated with improved progression-free survival irrespective of tumour location. In right-sided disease, early tumour shrinkage may identify a subgroup of patients who might respond to panitumumab.ClinicalTrials.gov identifierNCT00508404.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research